Please check your internet connection and try again.
# Walethmade bromide
*Note: There is no pharmaceutical agent known as "Walethmade bromide." It is highly probable this is a misspelling of **Aclidinium bromide** or a misinterpretation of a proprietary chemical name. The following information applies to **Aclidinium bromide** (a long-acting muscarinic antagonist).*
## Overview
Aclidinium bromide is an inhaled long-acting muscarinic antagonist (LAMA) that acts as a bronchodilator by inhibiting M3 receptors on airway smooth muscle. It is formulated as a dry powder for inhalation.
## Primary Indications
Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
## Adult Dosing
400 mcg (one inhalation) via the aerosol delivery device administered twice daily.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Not indicated for pediatric use.
## Dose Adjustments
No dosage adjustments are required for elderly patients or patients with renal or hepatic impairment.
## Contraindications
Hypersensitivity to aclidinium bromide, atropine, or any components of the inhalation powder. Not for use as a rescue medication for acute bronchospasm.
## Adverse Effects
Common: Headache, nasopharyngitis, cough, sinusitis.
Serious: Paradoxical bronchospasm (discontinue immediately), worsening of urinary retention, acute narrow-angle glaucoma symptoms (eye pain, blurred vision, halos).
## Key Drug Interactions
Avoid co-administration with other anticholinergic medications (e.g., ipratropium, tiotropium) due to the risk of additive anticholinergic effects.
## Monitoring
Monitor for signs/symptoms of paradoxical bronchospasm, urinary retention, and ocular changes. Chronic assessment of COPD severity via pulmonary function tests (FEV1).
## Clinical Pearls
* **Administration:** Ensure the patient is trained on the specific inhalation device. Emphasize that the device must be kept horizontal until inhalation.
* **Rescue Inhaler:** Patients should be advised to keep a short-acting beta-agonist (e.g., albuterol) available for the treatment of acute symptoms.
* **Anticholinergic systemic effects:** While absorption is low, counsel patients with narrow-angle glaucoma or prostatic hyperplasia to report new or worsening symptoms promptly.
***
**Educational Disclaimer:** This information is provided for educational purposes only. Drug information is subject to change, and specific clinical protocols may vary by institution. Always consult the latest FDA-approved prescribing information, the manufacturer’s product insert, or a clinical pharmacist before prescribing or administering any medication.
